Still betting on Nvidia? Our AI picked this stock instead; it’s up 96%+ THIS MONTH
Investing.com - Cymabay Therapeu reported on Monday third quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
Cymabay Therapeu announced earnings per share of $-0.280 on revenue of $0.00. Analysts polled by Investing.com EPS of $-0.300 on revenue of $0.
Cymabay Therapeu 's are down 20% and is trading at $3.610 , still down 20.66% from its 52 week high of $4.55 set on Monday, November 15, 2021.
Cymabay Therapeu follows other major Healthcare sector earnings this month
Cymabay Therapeu's report follows an earnings beat by J&J on Tuesday, October 18, 2022, who reported EPS of $2.55 on revenue of $23.79B, EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on Tuesday, November 1, 2022 with third quarter EPS of $1.98 on revenue of $6.94B, for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar